The fecal microbiota transplantation (fmt) global market report 2024 from The Business Research Company provides comprehensive market statistics, including global market size, regional shares, competitor market share, detailed segments, trends, and opportunities. This report offers an in-depth analysis of current and future industry scenarios, delivering a complete perspective for thriving in the industrial automation software market.
Fecal Microbiota Transplantation (FMT) Market, 2024 report by The Business Research Company offers comprehensive insights into the current state of the market and highlights future growth opportunities.
Market Size –
The fecal microbiota transplantation (FMT) market size has grown strongly in recent years. It will grow from $0.80 billion in 2023 to $0.85 billion in 2024 at a compound annual growth rate (CAGR) of 6.7%. The growth in the historic period can be attributed to growing awareness of gut microbiome, expanding therapeutic applications, increasing personalized medicine, adoption in gastroenterology practices, increasing number of clinical trials and increasing funding and investments.
The fecal microbiota transplantation (FMT) market size is expected to see strong growth in the next few years. It will grow to $1.12 billion in 2028 at a compound annual growth rate (CAGR) of 7.0%. The growth in the forecast period can be attributed to increasing incidence of clostridium difficile infections (CDI), rising prevalence of inflammatory bowel diseases, increasing research and development activities, rising geriatric population, and expanding healthcare infrastructure. Major trends in the forecast period include the development of standardized protocols for donor screening, stool preparation, advances in microbiome analysis, improved stool processing technologies, novel delivery methods, and the development of synthetic or standardized microbiota-based products.
Order your report now for swift delivery @
Scope Of Fecal Microbiota Transplantation (FMT) Market
The Business Research Company’s reports encompass a wide range of information, including:
1. Market Size (Historic and Forecast): Analysis of the market’s historical performance and projections for future growth.
2. Drivers: Examination of the key factors propelling market growth.
3. Trends: Identification of emerging trends and patterns shaping the market landscape.
4. Key Segments: Breakdown of the market into its primary segments and their respective performance.
5. Focus Regions and Geographies: Insight into the most critical regions and geographical areas influencing the market.
6. Macro Economic Factors: Assessment of broader economic elements impacting the market.
Fecal Microbiota Transplantation (FMT) Market Overview
Market Drivers –
The rising prevalence of gastrointestinal disorders is expected to propel the growth of the fecal microbiota transplantation (FMT) market going forward. Gastrointestinal (GI) disorders refer to a wide range of conditions that affect the gastrointestinal tract, which includes the esophagus, stomach, small intestine, large intestine (colon), rectum, and anus. The rise in gastrointestinal disorders is due to increased stress, sedentary lifestyles, and higher consumption of processed foods. Fecal microbiota transplantation is used in gastrointestinal disorders to restore healthy gut bacteria, particularly for treating recurrent Clostridioides difficile infections. For instance, in 2023, according to Crohn’s and Colitis Canada, a Canada-based non-profit organization, the number of people in Canada with IBD is increasing rapidly, from 322,600 in 2023 (0.8% of the population) to 470,000 in 2035 (1.1% of the population). In 2023, 11,000 people will be diagnosed (1 every 48 minutes), and by 2035, this will rise to 14,000 (1 every 38 minutes). Therefore, the rising prevalence of gastrointestinal disorders drives the growth of the fecal microbiota transplantation (FMT) market.
Market Trends –
Major companies operating in the fecal microbiota transplantation (FMT) market are focusing on developing innovative solutions, such as microbiota-based live biotherapeutics, to enhance treatment efficacy for gastrointestinal disorders. Microbiota-based live biotherapeutics refer to live microorganisms used as therapeutic agents to restore or modify the gut microbiome for treating various diseases. For instance, in November 2022, Ferring Pharmaceuticals, a Switzerland-based biopharmaceutical company, received US Food and Drug Administration (FDA) approval for REBYOTA (fecal microbiota, live-jslm), a novel first-in-class microbiota-based live biotherapeutic indicated for the prevention of recurrence of Clostridioides difficile infection (CDI) in individuals 18 years of age and older, following antibiotic treatment for recurrent CDI. REBYOTA is indicated for preventing Clostridioides difficile (C. difficile) infection recurrence in individuals 18 years of age and older following antibiotic treatment for recurrent CDI.
The fecal microbiota transplantation (FMT) market covered in this report is segmented –
1) By Type: Fermentation, Fresh, Cryopreservation
2) By Donor Type: Stool-Derived, Fecal-Derived, Whole-Microbiome Derived
3) By Indication: Clostridioides Difficile Infection, Inflammatory Bowel Disease, Metabolic Syndrome, Other Indications
4) By Administration Route: Oral, Rectal, Nasogastric, Colon Capsule
5) By End-User: Hospitals, Specialty Clinics, Other End-Users
Get an inside scoop of the fecal microbiota transplantation (fmt) market, Request now for Sample Report @
Regional Insights –
North America was the largest region in the fecal microbiota transplantation (FMT) market in 2023. The regions covered in the fecal microbiota transplantation (FMT) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Key Companies –
Major companies operating in the fecal microbiota transplantation (FMT) market are Ferring Pharmaceuticals, Johns Hopkins Medicine, Seres Therapeutics, Taconic Biosciences, Enterome, Rebiotix Inc., Finch Therapeutics Group Inc., Locus Biosciences, Yeda Research and Development Co. Ltd., Microbiotica Limited, CosmosID Inc., AOBiome, Synthetic Biologics Inc., Osel Inc., OpenBiome, Asia Microbiota Bank, Taymount Clinic, MicroBiome Therapeutics LLC, MaaT Pharma SA, Kallyope
Table of Contents
1. Executive Summary
2. Fecal Microbiota Transplantation (FMT) Market Report Structure
3. Fecal Microbiota Transplantation (FMT) Market Trends And Strategies
4. Fecal Microbiota Transplantation (FMT) Market – Macro Economic Scenario
5. Fecal Microbiota Transplantation (FMT) Market Size And Growth
…..
27. Fecal Microbiota Transplantation (FMT) Market Competitor Landscape And Company Profiles
28. Key Mergers And Acquisitions
29. Future Outlook and Potential Analysis
30. Appendix
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Follow Us On: